Reading preclinical peptide literature critically
Ten questions to ask of any preclinical paper, where secondary sources go wrong, and what it implies for how you characterise your own material.
Most of what is claimed about research peptides online traces back, eventually, to a small number of preclinical papers, and a great deal is lost in the translation. Researchers designing work with these compounds benefit from reading the primary literature with a specific set of questions in mind. This note sets out those questions, using the compounds in the Alphex catalogue as context. Nothing here recommends any use outside the laboratory. All Alphex products are for laboratory and in-vitro research only.
Questions to ask of any preclinical paper
- Which molecule, exactly? Sequence, salt form, supplier, purity, batch. A paper on thymosin beta-4 is not a paper on TB-500; a paper on GHK is not a paper on GHK-Cu. See Tβ4 versus TB-500.
- At what concentration, and is it plausible? In-vitro effects at high micromolar concentrations may be off-target. Convert everything to molar; mass comparisons across peptides of different size are meaningless. See calculating concentration.
- What model, and what does it model? A rodent tendon transection is a model of a surgical injury, not of a chronic human condition.
- What was the control? Vehicle matched for solvent and preservative; ideally a scrambled-sequence peptide of the same length and composition.
- How many animals or replicates, and was the analysis pre-specified? Small n and post-hoc subgroup analysis are the commonest sources of results that do not replicate.
- Who did the work? A literature concentrated in one group, without independent replication, is weaker evidence than the same number of papers from many groups. This is a notable feature of the BPC-157 literature specifically.
- Was the material characterised? Purity and identity stated, or "obtained from a supplier" with nothing more. Uncharacterised material is a plausible explanation for irreproducibility.
- Is the endpoint objective? Histology scored blind, biomechanical testing, quantitative assay, versus subjective grading.
- What is the effect size, not just the p value?
- Has anyone failed to replicate it? Negative results are under-published; absence of contradiction is not confirmation.
Where secondary sources go wrong
- Species and route erased. "Shown to accelerate healing" with no mention that it was rats, at a dose per kg, by injection.
- Fragment and parent conflated. The single most common error in this field.
- In-vitro presented as in-vivo. A cell-culture observation at 100 µM described as an effect.
- Development-stage claims. A clinical programme's results for a pharmaceutical product presented as applying to research-grade material of the same molecule. Retatrutide is the current example; see the GLP-3 (RT) guide.
- Citation chains. A blog cites a blog cites a review that cites a paper that says something narrower. Follow to the primary source every time.
Practical implications for your own work
Characterise the material (purity, identity, batch), state it in the methods, use matched vehicle controls, work in molar units with a net-content correction, and record batch numbers against results so that a later question about the reagent is answerable. See net peptide content and record keeping. Where a supplier, including this one, summarises literature, treat it as a pointer to sources rather than as evidence.
Alphex research peptides are supplied for laboratory and in-vitro research by qualified researchers only. They are not authorised for human or veterinary use.
Research use only. Alphex products are supplied exclusively for laboratory and in-vitro research by qualified researchers. They are not authorised for human or veterinary use, and nothing in this note is advice on any such use.
Published 8 May 2026. Alphex reviews research notes when the testing method, the catalogue or UK guidance changes.